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Background: From years 2001-2010, the Philippines ranked 4th
among theASEAN inannual average reporteddengueepisodeswith
45,409 cases. The WHO aims to achieve 50% reduction in dengue
mortality and25% reduction inmorbidityby2020 through integrat-
ing vector control approaches with vaccine introduction. Dengue
has yet to be prevented and 20 years of development has ﬁnally
yielded a candidate vaccine that has reached Phase III efﬁcacy clin-
ical trials: Sanoﬁ Pasteur’s dengue vaccine, a recombinant, live,
attenuated, tetravalent dengue vaccine (TDV).
Methods & Materials: This study aims to assess the cost-
effectiveness of different dengue vaccination strategies in the
Philippines from both a societal and a public payer’s perspec-
tive. Coudeville andGarnett’s (2012) dengue dynamic transmission
model was populated using Philippine-speciﬁc dengue vector, epi-
demiology, and cost data from literature and records review which
were validated through consultations with dengue experts from
the ﬁeld of family medicine, vaccine research, molecular biology,
epidemiology, public health, entomology, and infectious diseases.
Results: Main results show that over a period of 5 years,
conducting a school-based vaccination program targeting nine
year-olds for routine vaccination decreases dengue cases and
DALYs lost due to dengue relative to status quo by 24% and 26%,
respectively. Expanding the vaccination tomore children by adding
age cohorts close to nine years such as 10 to 11, 10 to 13, 10 to 15,
10 to 17, and 10 to 20 translates to more DALYs averted and less
dengue disease costs the government must shoulder.
Conclusion: Cost-effectiveness threshold prices following cost-
effectiveness deﬁnitionof less thanor equal to 1xGDPper capita for
the public payer and societal points of view are found to be 13 USD
per dose and 24 USD per dose, respectively. This cost-effectiveness
threshold set by the Philippines’ Department of Health is more
stringent than the WHO recommended cost-effectiveness thresh-
olds.
http://dx.doi.org/10.1016/j.ijid.2016.02.897
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Background: The recently emerged Middle East syndrome
coronavirus (MERS-CoV) can cause severe and fatal respiratory
diseases in humans. Antibodies against MESR-CoV can be found
in camels in the Middle East but also outside this regionThe
high prevalence of circulatingMERS-CoVneutralizing antibodies in
dromedary camels from different geographic regions may indicate
wide circulation of MERS-CoV in camels. The ongoing MERS-CoV
outbreak in the Middle East and the lack of treatment options or
licensed vaccines is of great concern. Vaccination of camels could
potentially prevent the spread of this virus.
Methods & Materials: We vaccinated 4 dromedary camels
twice with a 4 week interval with108 PFU MVA-S via both
nostrils and intramuscularly. Four control animals received non-
recombinant MVA (n=2) or PBS (n=2). Three weeks post-boost,
all animals were tested for presence speciﬁc antibody responses
by MERS-CoV ELSA and virus neutralization assay (VNT). Next, all
camels were challenged with a high dose of MERS-CoV and to
study the pathological changes, two animals per groupswere euth-
anized and necropsies were performed at day 4 and 14 pi. The
antibody response, and pathology were analyses by MERS-CoV-S
orMVAELISAs, -VNTs, qRT-PCR, virus titration, immunohistochem-
istry (IHC) and in situ hybridization (ISH).
Results: All vaccinatedanimaldevelopeddetectable serumneu-
tralizing MERS-CoV or MVA speciﬁc antibody titers 3 weeks post
boost vaccination. No clinical signs were observed in MVA-S vacci-
natedanimalsbutmildclinical signanda runnynosewereobserved
in control-vaccinated animals after virus challenge. Interestingly,
signiﬁcant reduction of infectious virus excreted and viral RNA
transcripts in the vaccinated animals nose after MERS-CoV chal-
lenge was observed as compared with control animals, and these
protection correlated with presence of neutralizing antibody to
MERS-CoV. In addition, in the nose of MVA-S vaccinated animals
at day 4 pi, a few MERS-CoV infected cells were detected by IHC
and ISH as compared with control camels. Interestingly, sera from
MVA-S vaccinated animals cross neutralized camelpox virus.
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Conclusion: Our results demonstrate that vaccination of camels
with MVA-S confers protects against MERS-CoV infection. In addi-
tion, induction of MVA speciﬁc antibody cross neutralize camelpox
virus, suggesting that MVA-MERS-S can be used as a dual vaccine
in dromedary camels.
http://dx.doi.org/10.1016/j.ijid.2016.02.898
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Background: Dengue is a mosquito-borne viral infection with
a very rapid global expansion during the last 50 years. This dis-
ease has become an important public health problem in Asia and
Latin America with over half the world’s population at risk1. Sanoﬁ
Pasteur is developing a recombinant, live, attenuated, tetravalent
dengue vaccine (CYD-TDV) for countries at-risk of dengue2. The
results from CYD-TDV trials are useful to observe the trends in
immunogenicity (GMT) titres across various countries.
OBJECTIVES: To assess immunogenicity titres after 3 doses of
CYD dengue vaccine in children, adolescents and adults up to 60
years by revisiting pre- and post-vaccination GMTs from Sanoﬁ
Pasteur CYD-TDV trials.
Methods&Materials: Dengue neutralizing antibody (Ab) levels
were assessed by a plaque neutralization test with a 50% endpoint
(PRNT50) for each serotype. In total, 25 clinical studies from Phase
I to Phase III have been included in the clinical development plan.
Of these 25 clinical studies, the integrated immunogenicity anal-
ysis presented here is based on results from 11 trials conducted
in 8 Asian countries (Philippines, Indonesia, Malaysia, Vietnam,
Thailand, Singapore, Australia, and India) and 6 Latin American
countries (Brazil, Colombia, Honduras, Mexico, Peru, and Puerto
Rico).
Results: Immune titres increased after 3 doses from baseline,
and higher GMTs were observed with increasing age and endemic-
ity in all countries considered at-risk of dengue. Further exploration
in older adults in Australia3 vaccinated with 3 doses of CYD-TDV,
revealed that both the 18-60 age group (N=655) and the 46-60 age
group (N=241) had similar GMTs which were higher than baseline.
Conclusion: Integrated analysis from CYD-TDV trials in chil-
dren, adolescents and adults up to 60 years of age showed a
consistent ﬁnding of higher GMTs in the vaccinated arm versus
control arm. Subjects who received 3 doses of CYD-TDV elicited
a balanced immune response against all four serotypes.
References: WHO Dengue factsheet No. 117 (updated May
2015) Guy B and al., Vaccine, 2011 Toressi et al, Vaccine, 2015
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Background: Cystic Echinococcosis (CE) is one of the most
important zoonosis parasite diseases which caused by the larval
stage of Echinococcus granulosus (Eg). The Eg14-3-3 protein is a
vaccine candidate antigen which exists in different development
stages of E. granulosus. The basement of vaccine design strate-
gies is identiﬁcation the most efﬁcacious epitopes of the antigen.
This study presents linear and conformational B cell epitopes of the
Eg14-3-3 antigen via computational tools.
Methods & Materials: The protoscoleces (PSC) of E. granulo-
sus was aspirated from infected lungs and livers of slaughtered
sheep (Tabriz, Iran) and then DNA samples were extracted. The
polymerase chain reaction (PCR) was performed using speciﬁc
primers (forward: ATGTCTTCTCTCAGTAAGCGCGA and reverse:
ATCGGCTTTCGGCGGTTCAG) and basing on the sequence in Gen-
Bank (Access No. AY942149). After sequencing the PCR products,
our regional Eg14-3-3 sequence was utilized (the sequence of our
local Eg14-3-3 shall be published soon). The linear B-cell epitopes
were predicted by Bepipred Linear Epitope Prediction algorithm
with threshold 0.35. The conformational B-cell epitopes were pre-
dicted using a sequence-based server named CBTOPE which uses
the support vector machine (SVM) threshold -0.3, and also the
three dimensional (3D) properties of the antigen such as, Rela-
tive SolventAccessibility, Number of TransmembraneDomains and
protein tertiary structure prediction. The structural details of Eg14-
3-3which are usable in the epitope-based vaccine design evaluated
via SCRATCH Protein Predictor.
Results: The Best linear B-cell epitopes were selected based
on their length (<9 amino acids) and score (highest), so that
the high scales consist of ATEVAEGDMQTT, DTLPEESYK, EQKHDG-
DAK and TGDERKQASDN. Based on CBTOPE algorithm ﬁve high
